NCT01724554View on ClinicalTrials.gov

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Central Retinal Vein OcclusionProliferative Diabetic Retinopathy
Interventions
DRUG

Intravitreal Aflibercept Injection

Aflibercept administered to the eye intravitreally either every month or every other month.

Trial Locations (1)

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Ophthalmic Consultants of Boston

OTHER

NCT01724554 - Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion | Biotech Hunter | Biotech Hunter